{"filings":[{"id":2272239,"accession_number":"0001193125-26-352370","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2026-08-14T20:27:18+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"OPKO Health issues $125M additional senior secured notes due 2044","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $125M additional senior secured notes under amended Note Purchase Agreement dated Aug 13, 2026.","Notes mature July 17, 2044; interest at 3-month SOFR + 7.5% (4% floor), payable quarterly.","Secured by EirGen's royalty payments from Pfizer profit share and mazdutide payments from Eli Lilly, capped at $187.5M.","Guarantors OBL and EirGen guarantee notes; security interest in certain assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1886039,"accession_number":"0001193125-26-318069","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2026-07-27T20:08:03+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health Q2 2026 net loss narrows to $8.4M; provides FY 2026 revenue guidance $560-585M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $163.5M vs $156.8M YoY; operating loss improved to $7.0M from $60.0M.","Net loss $8.4M ($0.01/share) vs $148.4M ($0.19/share) in Q2 2025.","Diagnostics revenue $74.5M (down from $101.1M due to oncology asset sale to Labcorp); pharma product revenue $42.9M.","Cash and equivalents $314.4M; $105.3M of stock repurchased under $200M program.","FY 2026 total revenue guidance $560-585M; Q3 2026 revenue guidance $131-142M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1138319,"accession_number":"0001193125-26-275818","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2026-06-18T20:06:31+00:00","items":["5.07"],"status":"ready","headline":"OPKO Health stockholders elect all 11 director nominees and approve 2026 equity plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; Phillip Frost received 423.7M for, 40.2M against, 296K abstain.","2026 Equity Incentive Plan approved with 440.1M for, 23.7M against, 348K abstain.","Non-binding advisory vote on executive compensation passed: 446.2M for, 17.5M against.","Ratification of Ernst & Young as auditor for FY 2026 approved: 535.1M for, 6.1M against.","No other matters were considered or voted upon at the June 18, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99942,"accession_number":"0001193125-26-186939","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health Q1 revenue falls to $124.2M, net loss narrows; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $124.2M vs $149.9M YoY; net loss $54.8M ($0.07/sh) from $67.6M ($0.10/sh).","Pharma revenue $38.0M (+9% YoY); Diagnostics $72.2M, down from $102.8M due to Labcorp oncology asset sale.","Operating loss improved to $51.0M from $67.2M; cash $341.9M; $92M of stock repurchased under $200M authorization.","Phase 1 trials started for MDX2301 (COVID-19 prevention) and MDX2003 (B-cell lymphoma); in vivo CAR-T platform advancing.","FY2026 guidance reaffirmed: total revenue $530-560M; total costs $725-750M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":124196000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116250,"accession_number":"0001193125-26-116122","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OPKO Health appoints former CFO Subbarao Uppaluri as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Subbarao V. Uppaluri, PhD, appointed to OPKO board effective March 18, 2026; term expires at 2026 annual meeting.","Uppaluri previously served as OPKO's SVP & CFO from 2007-2012 and consultant until 2014.","Appointment fills board vacancy created by passing of Dr. Richard Krasno, who served since 2017.","Board determined Uppaluri independent under SEC and Nasdaq rules; expected to join Compensation Committee.","Standard non-employee director compensation and indemnification agreement apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116249,"accession_number":"0001193125-26-076575","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health Q4 revenue $148.5M, net loss $31.3M; Regeneron deal >$1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $148.5M (down 19% YoY); net loss $31.3M ($0.04/share) vs $14.0M income in Q4 2024.","Regeneron collaboration for multispecific antibodies: upfront + milestones >$200M per program, total >$1B.","Pharmaceuticals revenue $43.7M (+17% YoY); NGENLA profit share $12.5M, Rayaldee $8.8M.","Diagnostics revenue $71.1M (down 31% YoY) on asset sale; operating loss improved to $18.3M from $21.7M.","FY 2026 guidance: total revenue $530-560M; total costs $725-750M; R&D $125-135M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":606879000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132706,"accession_number":"0001193125-25-256325","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Q3 net income $21.6M; Regeneron collaboration with $1B+ potential; sells BioReference oncology to Labcorp for $225M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 consolidated revenues $151.7M, down 12.6% YoY; operating income $48.1M vs $14.2M; diluted EPS $0.03 flat.","Entered multi-program Regeneron collaboration for multispecific antibodies; upfront plus milestones >$200M per program, total potential >$1B.","Completed sale of BioReference oncology assets to Labcorp for $225M ($192.5M cash + $32.5M earnout); net gain of $101.6M recorded.","Pharmaceuticals revenue $37.7M (Rayaldee $7.5M, up 29%); diagnostics revenue $95.2M, down due to prior-year asset sales.","Cash, cash equivalents and restricted cash $428.9M at Sep 30, 2025; $73.8M used in share repurchase program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":458429000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149231,"accession_number":"0001193125-25-203530","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"OPKO completes sale of BioReference oncology assets to Labcorp for $192.5M cash plus earnout","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Transaction closed Sept 15, 2025; Labcorp paid $192.5M at closing, with up to $32.5M earnout.","Assets include BioReference's oncology and oncology-related clinical testing services across the U.S.","OPKO to use portion of proceeds for share repurchase; continuing ops had ~$300M revenue in 2024.","CEO Phillip Frost says deal positions BioReference to focus on core testing and 4Kscore franchise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149230,"accession_number":"0000950170-25-100891","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health Q2 revenue $156.8M down 14% YoY; net loss includes $91.7M convertible note charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $156.8M vs $182.2M in Q2 2024; net loss $148.4M ($0.19/share) vs $10.3M loss ($0.01) prior year, including $91.7M non-recurring convertible note expense.","Diagnostics revenue $101.1M (-22% YoY) on lower clinical test volume from BioReference asset sale; operating loss improved to $18.2M from $26.6M.","Pharmaceuticals revenue $40.7M (flat); operating loss $28.7M vs $24.8M, driven by higher R&D for pipeline programs.","Board authorized additional $100M share repurchase, total capacity $200M; $58.5M repurchased through June 30.","FDA approved 4Kscore Test without DRE; Merck Phase 1 EBV vaccine and multiple pipeline programs advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":306759000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168254,"accession_number":"0000950170-25-079098","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OPKO Health grants stock options and bonuses to CEO Frost and other executives","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Compensation Committee granted stock options for 500,000 shares to CEO Phillip Frost, each at $1.31 exercise price.","CEO Frost receives $480,000 cash bonus; Vice Chairmen Hsiao and Zerhouni each get $450,000 bonuses and 500,000 options.","EVP Admin Steven Rubin: 437,500 options + $400,000 bonus; CFO Adam Logal: 437,500 options + $475,000 bonus.","Options vest ratably over four years and expire on the tenth anniversary of the grant date.","Total options granted to named officers: 2,375,000 shares; total bonuses: $2,255,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168253,"accession_number":"0001437749-25-013848","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health Q1 revenue down 14% to $149.9M; net loss narrows to $67.6M; signs $225M Labcorp asset sale","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $149.9M vs $173.7M YoY; net loss $0.10 per share vs $0.12 per share.","Signed definitive agreement to sell oncology testing assets to Labcorp for up to $225M ($192.5M at close + $32.5M earnout); expected close H2 2025.","Board authorized additional $100M for stock buyback (total $200M); ~$40.2M repurchased under prior program since July 2024.","Post-quarter: exchanged $159.2M convertible notes for 121.4M shares + $63.5M cash.","Collaboration with Entera Bio for oral GLP-1/glucagon tablet; OPKO purchased 3.7M Entera shares at $2.17/share."],"consensus_eps_estimate":-0.0693,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":149952000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168252,"accession_number":"0001437749-25-012806","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"OPKO Health stockholders elect all 11 director nominees, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected; highest vote for Alice Lin-Tsing Yu (444.8M for).","Say-on-pay advisory vote passed with 439.3M for, 11.0M against.","Ratification of Ernst & Young as auditor for FY 2025 passed with 522.7M for.","Broker non-votes of ~76.2M on director and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168251,"accession_number":"0001437749-25-010494","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"OPKO Health exchanges $159.2M convertible notes for 121.4M shares and $63.5M cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $152.5M (Mar 27) plus $6.75M (Mar 28) of 3.75% Convertible Senior Notes due 2029.","Issued 121,437,998 common shares plus $63.5M cash (incl. accrued interest) in exchange.","Closing occurred April 1, 2025; all exchanged notes retired and no longer outstanding.","Shares issued without registration, relying on Section 4(a)(2) exemption.","Noteholders represented QIB or accredited investor status for the exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185439,"accession_number":"0001437749-25-009701","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"OPKO Health to exchange $152.5M convertible notes for 116.7M shares and ~$60.1M cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchange of $152,471,000 principal of 3.75% Convertible Senior Notes due 2029 for 116,706,310 common shares and ~$60.1M cash, including accrued interest.","Closing scheduled April 1, 2025; Exchanged Notes will be retired.","Shares issued unregistered under Section 4(a)(2) based on Noteholder representations as QIBs or accredited investors.","Transaction reduces debt and interest expense but dilutes existing shareholders by adding 116.7M new shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185438,"accession_number":"0001437749-25-006898","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"OPKO Health to sell oncology testing assets to Labcorp for up to $225M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price: $192.5M at closing plus up to $32.5M in earnout based on performance.","Divested assets generate ~$85-100M in annual revenue; deal expected to close H2 2025.","BioReference retains core NY/NJ clinical testing and 4Kscore franchise (~$300M 2024 revenue).","Labcorp expects acquisition to be accretive to earnings in year one.","Transaction includes customary closing conditions and state regulatory approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185437,"accession_number":"0001437749-25-005468","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health reports Q4 net income of $14M, revenue $183.6M; BARDA/Merck milestones boost pharma","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated Q4 revenue $183.6M vs $181.9M; net income $14.0M ($0.01 diluted EPS) vs net loss of $66.5M in Q4 2023.","Pharma segment operating loss narrowed to $2.1M from $16.0M; IP transfer revenue rose to $43.1M (includes $12.5M Merck milestone, $23.8M BARDA).","Diagnostics revenue fell to $103.1M from $124.2M on asset sales; operating loss improved to $21.7M from $42.3M.","BARDA awarded additional $51M for COVID/influenza antibodies; total awards to ModeX now $110M, up to $205M if all options exercised.","Capital actions: repurchased $17M principal notes, 10.9M shares for $16.5M; reduced share count 10% in 2024; sold part of BioReference for $237.5M."],"consensus_eps_estimate":-0.0693,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":713142000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185436,"accession_number":"0001437749-25-001220","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OPKO Health management presents at J.P. Morgan Healthcare Conference; no material news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Management attended investor meetings at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.","Presentation materials furnished as Exhibit 99.1 are available on the company's website.","No specific financial results, guidance changes, or material corporate developments were announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202028,"accession_number":"0001437749-24-033922","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO reports Q3 net income $24.9M; sells BioReference assets for $237.5M, authorizes $100M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $173.6M vs $178.6M YoY; net income $24.9M ($0.03/diluted) vs net loss $84.5M ($0.11) in 2023.","Completed sale of select BioReference Health assets to Labcorp for $237.5M; continues oncology/urology nationwide.","Entered $250M note purchase agreement with HealthCare Royalty secured by NGENLA profit share payments from Pfizer.","Board authorized $100M share repurchase program; repurchased 14.9M shares for $23.8M in Q3 and 8.7M more through Nov 6.","Awarded $51M additional BARDA funding ($26.9M COVID, $24.1M influenza) for ModeX multispecific antibodies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":529504000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218073,"accession_number":"0001437749-24-029310","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["1.02","2.01","7.01","9.01"],"status":"ready","headline":"OPKO Health closes $237.5M sale of BioReference clinical diagnostics assets to Labcorp","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Labcorp acquired select BioReference diagnostics assets outside NY/NJ for $237.5M cash.","Acquired assets generate ~$100M annual revenue; OPKO retains NY/NJ and oncology/urology ($400M).","BioReference repaid $9.7M credit facility with JPMorgan; no prepayment penalty.","Pro forma cash increases to ~$273M; estimated gain on sale ~$122.6M.","OPKO Chairman cites transaction as key step toward profitability and focus on core testing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218072,"accession_number":"0001437749-24-025180","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO reports Q2 net loss $10.3M; enters $250M note deal, plans $100M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenues $182.2M (down from $265.4M YoY); operating loss $61.7M vs income $7.0M; net loss $0.01/share.","NGENLA global launch ongoing; earned $6.3M gross profit share from Pfizer in Q2 (up from $3.8M).","Entered $250M note purchase agreement with HealthCare Royalty secured by NGENLA profit share; retains milestone upside.","Board authorized $100M share repurchase program (~10.1% of shares outstanding).","Sale of BioReference laboratory assets to Labcorp for $237.5M expected close end of Q3 2024."],"consensus_eps_estimate":-0.1145,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":355872000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218071,"accession_number":"0001437749-24-023634","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OPKO Health grants 2.375M RSUs and bonuses to five named executive officers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Phillip Frost: 500,000 RSUs + $480,000 bonus; other NEOs similar awards.","Total RSU grants: 2,375,000 shares; vest 50% on 2nd anniversary, then ratably.","CFO Adam Logal: 437,500 RSUs and $475,000 bonus.","Compensation Committee approved on July 24, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218070,"accession_number":"0001437749-24-022919","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"OPKO Health issues $250M senior secured notes due 2044, secured by NGENLA profit share payments from Pfizer","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Notes bear interest at 3-month SOFR + 7.5% (floor 4%); interest-only for first 4 years.","No principal payments required before July 2028; principal repaid from NGENLA profit share payments.","Proceeds provide non-dilutive capital for R&D, including multispecific antibody programs, and potential share/convertible note repurchases.","Exit fee of 3% on repayment; make-whole provision up to 200% of principal if prepaid after year 5.","OPKO retains full benefit of up to $100M in remaining milestone payments from Pfizer for NGENLA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238020,"accession_number":"0001437749-24-015074","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health to sell BioReference assets to Labcorp for $237.5M; Q1 net loss $81.8M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Agreed to sell select BioReference Health assets to Labcorp for $237.5M; assets generate ~$100M annual revenue; closing expected H2 2024.","Q1 total revenue $173.7M (down 27% YoY); net loss $81.8M ($0.12/share) vs $18.3M loss a year ago.","Issued $230M 3.75% convertible notes due 2029; exchanged $144.4M of existing 4.50% notes; used $50M to repurchase common stock.","FDA cleared IND for MDX2001 tetraspecific antibody for solid tumors; Phase 1 trial enrollment expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255495,"accession_number":"0001437749-24-010069","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"OPKO Health stockholders approve share increase to 1.25B, elect all 11 directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized share increase from 1B to 1.25B approved with 492.4M for, 37.9M against.","All 11 director nominees elected; votes ranged from 409.3M to 438.3M for each.","Non-binding advisory vote on named executive officer compensation passed with 431.1M for.","Ratification of Ernst & Young as independent auditor for FY2024 approved with 519.6M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255494,"accession_number":"0001437749-24-009695","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"OPKO Health sells BioReference clinical diagnostics business to LabCorp for ~$237.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Asset Purchase Agreement with LabCorp for $237.5M cash, excluding oncology/urology and NY/NJ operations.","Transaction includes transfer of certain BioReference employees; no financing condition required.","Closing subject to HSR clearance and customary conditions; 180-day outside date with potential extensions.","Termination fee payable by LabCorp in certain circumstances if regulatory clearance fails.","OPKO retains nationwide oncology/urology and all NY/NJ operations post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255487,"accession_number":"0001437749-24-009735","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K/A","filed_at":"2024-03-28T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"OPKO files 8-K/A to update investor presentation after BioReference asset sale to LabCorp","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Asset Purchase Agreement with LabCorp for BioReference Health, LLC signed March 27, 2024.","This amendment replaces the January investor presentation with a March 27, 2024 version.","Exhibit 2.1 (Asset Purchase Agreement) filed with schedules omitted; no deal value disclosed.","No financial or operational details from the updated presentation available in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255493,"accession_number":"0001437749-24-005707","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health Q4 revenue $181.9M; net loss narrows to $0.09/sh; $230M convertible notes issued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $181.9M vs $185.4M in prior-year quarter; net loss $65.5M ($0.09/sh) vs $85.2M ($0.11/sh).","Diagnostics segment revenue fell 11% to $124.2M on lower reimbursement and COVID-19 testing decline.","Pharmaceuticals revenue rose to $43.0M, driven by international operations and RAYALDEE sales of $9.3M.","After quarter end, OPKO sold $230M of 3.75% convertible senior notes due 2029 and used $50M to repurchase stock.","BioReference Health REACH program reduced annualized expenses by $10.1M; operating loss $42.3M including $4.7M non-recurring."],"consensus_eps_estimate":-0.0693,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":863495000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255492,"accession_number":"0001437749-24-003630","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-02-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OPKO Health director Alexis Borisy to step down at 2024 annual meeting, board to shrink to 11","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alexis Borisy will not stand for reelection at the 2024 Annual Meeting on March 28, 2024.","His departure is not due to any disagreement with the company.","Board size will decrease to 11 members after his term ends."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255491,"accession_number":"0001437749-24-002036","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-01-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"OPKO Health terminates share lending agreement, receives ~21.7M shares back as treasury","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Jan 22, 2024, terminated share lending agreement with Jefferies Capital Services dated Feb 4, 2019.","Original loan of ~30M shares in connection with $200M convertible notes due 2025; prior reduction of ~8,313,000 shares.","All outstanding borrowed shares returned to Company upon termination, to be held as treasury shares.","No other details on reason or financial impact provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255490,"accession_number":"0001437749-24-001007","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"OPKO Health closes $301M convertible note offering, repurchases stock and existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $230M of 144A Notes and $71.1M of Affiliate Notes (3.75% due 2029); net proceeds $221.4M from 144A.","Used $50M to repurchase ~55.1M shares of common at $0.9067/sh; used $146.3M to retire $144.4M of 4.50% notes due 2025.","Retired $55M of existing 5% convertible notes (plus $16.1M accrued interest) via exchange for Affiliate Notes.","Conversion price initially $1.15/share; notes mature Jan 15, 2029; holders may convert under specified conditions.","Affiliate purchasers include CEO Phillip Frost (Frost Gamma Investments) and Vice-Chair Jane H. Hsiao."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255489,"accession_number":"0001437749-24-000675","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"OPKO Health prices $200M 3.75% convertible notes due 2029; funds buyback of common stock and 2025 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$200M principal, 3.75% rate, matures Jan 15, 2029; initial conversion price ~$1.15 (26.8% premium).","Affiliates (CEO and others) exchange $71.1M of existing 5% prom notes for affiliate notes.","Net proceeds ~$192.5M; ~$50M for stock repurchases at $0.9067/share, ~$146.3M to retire ~$144.4M of 4.50% notes due 2025.","Offering expected to close Jan 9, 2024; initial purchaser option for additional $30M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255488,"accession_number":"0001437749-24-000456","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"OPKO Health launches $200M convertible notes offering due 2029; plans stock and note buybacks","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Private offering of $200M aggregate principal of Convertible Senior Notes due 2029, plus $30M greenshoe.","Net proceeds include up to $50M for repurchases of common stock from note purchasers in negotiated transactions.","Also intends to repurchase a portion of outstanding 4.50% Convertible Senior Notes due 2025 from net proceeds.","Affiliates of CEO and Vice-Chairman expect to exchange $70M of existing 5% convertible notes for new 2029 notes.","Interest rate, conversion rate set at pricing; conversions settled in cash, stock, or combination at company's election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272955,"accession_number":"0001437749-23-030387","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Q3 net loss $84.5M; revenues flat; BARDA awards $59M contract for ModeX","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $84.5M ($0.11/sh) vs $86.1M; operating loss improved to $64.4M from $87.8M YoY.","Diagnostics revenue $131.7M (-8% YoY); operating loss improved 41% to $29.1M on cost cuts.","Pharmaceuticals revenue $40.7M (+26% YoY) driven by international sales; RAYALDEE up to $7.3M.","ModeX awarded $59M BARDA contract for multispecific antibodies; up to $109M in milestones.","NGENLA approved in 48 markets; U.S. gross profit sharing began August 2023; cash $138.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":681591000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272954,"accession_number":"0001437749-23-029516","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K/A","filed_at":"2023-10-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"OPKO Health Board sets annual say-on-pay frequency after shareholder vote","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["At June 22, 2023 annual meeting, shareholders voted on frequency of future say-on-pay votes; one year received most votes.","Board of Directors has determined to hold a non-binding advisory vote on executive compensation every year.","Determination will remain in effect until Board decides a different frequency or next required vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289794,"accession_number":"0001437749-23-027034","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OPKO subsidiary ModeX awarded $59M BARDA contract for multispecific antibody against SARS-CoV-2, up to $168M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ModeX (OPKO subsidiary) received initial $59M from BARDA for MSTAR multispecific antibody Phase 1 trial against SARS-CoV-2.","Up to $109M additional contingent on milestones for developing antibodies against influenza and other viral pathogens.","Total potential contract value $168M; part of HHS' Project NextGen for innovative COVID-19 vaccines and therapeutics.","Gene-based delivery methods (mRNA/DNA vectors) will be developed to leverage body's natural protein production.","In March 2023, ModeX entered exclusive worldwide license with Merck for Epstein-Barr virus vaccine candidate MDX2201."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289793,"accession_number":"0001437749-23-021927","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO reports Q2 2023 net loss of $19.6M; receives $90M milestone from Pfizer for NGENLA approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $265.4M, down from $309.9M YoY; operating income $7.0M vs loss of $10.7M.","Pharma segment revenue rose to $43.5M; $94.9M IP transfer revenue included $90M NGENLA milestone.","Diagnostics revenue fell to $127.0M from $186.8M due to lower COVID-19 testing volume and reimbursement.","Cash and equivalents $108.1M, excluding the $90M milestone payment expected in August 2023.","NGENLA approved in 44 markets; profit sharing with Pfizer begins from August 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":502995000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310706,"accession_number":"0001437749-23-019033","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"OPKO subsidiary BRH cuts revolver from $75M to $50M, extends maturity to Aug 2025/conditional","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate revolving commitment reduced from $75M to $50M.","Maturity extended from August 2024 to earlier of August 2025 or 90 days before maturity of any material OPKO-level debt.","Interest rate benchmark switched from LIBOR to forward-looking term SOFR.","Revised commitment fee rate; full terms to be filed in Q2 2023 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310705,"accession_number":"0001437749-23-018259","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"OPKO Health stockholders elect 12 directors, approve Say on Pay, ratify auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 director nominees elected; top vote-getter Krasno with 443.9M for, lowest Nabel with 344.9M for.","Say-on-pay approved non-bindingly: 437.6M for, 14.8M against, 1.1M abstain.","Stockholders selected 1-year frequency for future say-on-pay votes (439.2M votes for 1-year).","Ratification of Ernst & Young as auditor for 2023: 550.8M for, 5.5M against, 1.1M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310704,"accession_number":"0001437749-23-015320","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OPKO Health grants 3.8M options at $1.58 and $2.155M bonuses to top execs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board grants 3.8M stock options to five named executives at $1.58 strike, vesting over 4 years.","CEO Phillip Frost awarded 800,000 options and $480,000 bonus.","CFO Adam Logal receives 700,000 options and $375,000 bonus.","Total bonuses for named executives amount to $2.155 million, ranging from $375k to $480k.","Options expire on the 10th anniversary of the May 18, 2023 grant date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310703,"accession_number":"0001437749-23-012324","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health Q1 revenue down 28% YoY to $237.6M; net loss narrows to $0.02/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pharmaceuticals revenue up to $40.4M (vs $36.6M) driven by Rayaldee and IP transfers including $50M Merck upfront.","Diagnostics revenue plunged to $132.4M from $286.6M due to lower COVID testing and GeneDx sale; operating loss of $40M.","ModeX entered license deal with Merck for EBV vaccine MDX-2201; potential milestones up to $872.5M plus royalties.","Net loss improved to $18.3M ($0.02/share) from $55.4M ($0.08/share) in Q1 2022; cash $110.8M not including $50M April payment.","Rayaldee sales grew to $6.6M from $5.1M; NGENLA approved in 41 countries, sales underway in 17."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":237577000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329334,"accession_number":"0000944809-23-000015","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"OPKO subsidiary ModeX licenses EBV vaccine to Merck for $50M upfront, up to $872.5M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["ModeX grants Merck exclusive worldwide license for MDX-2201, a preclinical nanoparticle vaccine targeting EBV.","OPKO receives $50M upfront; eligible for up to $872.5M in development and commercial milestones.","Tiered royalties from high single digits to low double digits on global sales of the vaccine product.","Joint research program until IND filing; Merck to lead clinical development and commercialization thereafter.","A portion of payments may be payable to Sanofi under ModeX's prior in-license agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329333,"accession_number":"0000944809-23-000010","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health Q4 2022 revenue drops to $185.4M; net loss $85.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $185.4M vs $401.3M YoY; net loss $85.2M ($0.11/share) includes $49.1M non-cash charge on GeneDx investment.","Diagnostics revenue $139.4M (down from $362.8M) due to COVID-19 testing decline; BioReference processed 0.1M PCR tests vs 2.7M.","Pharmaceuticals revenue $37.9M (up from $35.3M) driven by RAYALDEE ($9.1M) and IP transfer ($8.1M); NGENLA sales underway in 15 countries.","Operating loss $55.3M vs $63.1M; cash $153.2M as of Dec 31, 2022.","BioReference implementing cost-cutting initiatives to return to profitability after COVID-19 testing decline."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":1004196000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329332,"accession_number":"0000944809-23-000008","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["1.01","2.03","3.02"],"status":"ready","headline":"OPKO extends $55M convertible notes maturity to Jan 2025, lowers conversion price to $1.66","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Original $55M 5% convertible notes due Feb 2023 amended to extend maturity to Jan 31, 2025.","Conversion price reset to $1.66 (10-day VWAP plus 25% premium), down from $5.00 per share.","Interest continues to accrue from last payment date; other terms unchanged.","Notes and shares issuable upon conversion were not registered under Securities Act, relying on Section 4(a)(2) exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329331,"accession_number":"0000944809-23-000002","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"OPKO Health notifies holders of repurchase right on $3M convertible notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repurchase right for 3.00% Convertible Senior Notes due 2033 pursuant to Indenture Section 3.3(c).","Approximately $3.0 million aggregate principal amount of the Notes remain outstanding.","Holders can require OPKO to purchase Notes at 100% of principal plus accrued interest.","Last date for holders to exercise repurchase right is January 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346944,"accession_number":"0000944809-22-000046","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health reports Q3 net loss of $86.1M as COVID testing revenue collapses","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $179.7M, down 53% YoY from $385.8M, driven by lower COVID-19 testing.","Diagnostics revenue $142.8M (vs. $340.1M); BRL processed ~0.2M COVID PCR tests vs 2.2M last year.","Pharmaceuticals revenue $32.4M (vs. $36.9M); NGENLA royalties began; RAYALDEE sales $6.9M.","Operating loss $87.8M vs operating income $37.8M; net loss $0.11 per share vs $0.04 income.","BRL cut >$100M annualized costs; cash and equivalents $180.8M at Sept. 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":818856000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363331,"accession_number":"0000944809-22-000043","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2022-08-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"OPKO Health’s Senior VP and BioReference CEO Jon R. Cohen retires; receives $1M severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jon R. Cohen retired as SVP of OPKO, Executive Chairman & CEO of BioReference, and board member effective Aug 16, 2022.","He will serve as advisor through Dec 31, 2022, then consultant through Aug 2023.","Severance includes $1,000,000 aggregate and full vesting acceleration of all unvested stock options as of Dec 31, 2022.","Retirement not due to any disagreement with the company on operations, policies, or practices.","Severance agreement includes confidentiality, non-solicitation, non-disparagement, and cooperation clauses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363330,"accession_number":"0000944809-22-000041","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health Q2 net loss of $101.7M on $309.9M revenue; NGENLA launch, ModeX acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Acquired ModeX for $300M in stock; Dr. Zerhouni appointed President/Vice Chairman, Dr. Nabel Chief Innovation Officer.","Pfizer launched NGENLA in Europe/Japan; OPKO received $85M milestone payment.","Closed GeneDx sale to Sema4 for ~$322M upfront (cash + shares) plus up to $150M milestones.","BRL diagnostics revenue fell to $186.8M from $397.2M; COVID PCR tests dropped to 0.9M from 2.8M.","Net loss includes $71.2M non-cash charge from Sema4 stock decline; operating loss of $10.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":639111000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363329,"accession_number":"0000944809-22-000035","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2022-07-15T23:59:59+00:00","items":["1.01","5.07","9.01"],"status":"ready","headline":"OPKO Health settles DOJ investigation for $10M; admits improper physician payments","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves False Claims Act allegations; total payment $10M plus 1.5% annual interest from Sep 2021.","Admits BioReference paid above-fair-market rent to physician groups from Jan 2013 to Mar 2021.","OPKO and BioReference entered a 5-year Corporate Integrity Agreement with enhanced compliance obligations.","Annual meeting approved all 13 director nominees, say-on-pay, and equity plan increase to 60M shares.","Ernst & Young ratified as independent auditor for FY 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383109,"accession_number":"0000944809-22-000029","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2022-05-13T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"OPKO Health acquires ModeX Therapeutics for $300M in stock; appoints Dr. Zerhouni as President","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger consideration of $300M paid via 89,907,310 shares of OPKO common stock.","Dr. Elias Zerhouni appointed President and Vice Chairman; Dr. Gary Nabel named Chief Innovation Officer and director.","Alexis Borisy appointed to board; receives 312,612 restricted shares and options.","Frost Gamma Investments Trust and holders of ~88% of consideration shares subject to 4-year lockup.","Zerhouni employment: $900K base, target bonus ≥50%; Nabel: $750K base, target bonus ≥50%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383108,"accession_number":"0000944809-22-000023","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health Q1 net loss $55.4M; completes ModeX acquisition for $300M and GeneDx sale","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 consolidated revenue $329.2M (down from $545.2M); net loss $55.4M ($0.08) vs net income $31.1M ($0.05) prior year.","Diagnostics revenue $286.6M (down from $507.0M) due to lower COVID-19 testing: 2.0M tests vs 4.1M YoY.","Acquired ModeX Therapeutics for $300M in OPKO common stock; Dr. Elias Zerhouni named President and Vice Chairman.","Closed sale of GeneDx to Sema4 for ~$322M upfront (cash + stock) plus up to $150M in milestones.","Pfizer launched NGENLA in Germany/Japan; OPKO earned $85M milestones. RAYALDEE launched in Germany by Vifor."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":329219000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-09T23:59:59+00:00|383108"}